Vis enkel innførsel

dc.contributor.authorStunes, Astrid Kamilla
dc.contributor.authorWestbroek, Irene
dc.contributor.authorGustafsson, Björn
dc.contributor.authorFossmark, Reidar
dc.contributor.authorWaarsing, Jan H
dc.contributor.authorEriksen, Erik Fink
dc.contributor.authorPetzold, Christiane
dc.contributor.authorReseland, Janne Elin
dc.contributor.authorSyversen, Unni
dc.date.accessioned2019-10-10T11:14:34Z
dc.date.available2019-10-10T11:14:34Z
dc.date.created2011-09-05T13:48:18Z
dc.date.issued2011
dc.identifier.citationBMC Endocrine Disorders. 2011, 11 (11), .nb_NO
dc.identifier.issn1472-6823
dc.identifier.urihttp://hdl.handle.net/11250/2621385
dc.description.abstractBackground Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore these effects we have examined the effect of the PPARalpha agonists fenofibrate and Wyeth 14643, and the PPARgamma agonist pioglitazone, on bone mineral density (BMD), bone architecture and biomechanical strength in ovariectomized rats. Methods Fifty-five female Sprague-Dawley rats were assigned to five groups. One group was sham-operated and given vehicle (methylcellulose), the other groups were ovariectomized and given vehicle, fenofibrate, Wyeth 14643 and pioglitazone, respectively, daily for four months. Whole body and femoral BMD were measured by dual X-ray absorptiometry (DXA), and biomechanical testing of femurs, and micro-computed tomography (microCT) of the femoral shaft and head, were performed. Results Whole body and femoral BMD were significantly higher in sham controls and ovariectomized animals given fenofibrate, compared to ovariectomized controls. Ovariectomized rats given Wyeth 14643, maintained whole body BMD at sham levels, while rats on pioglitazone had lower whole body and femoral BMD, impaired bone quality and less mechanical strength compared to sham and ovariectomized controls. In contrast, cortical volume, trabecular bone volume and thickness, and endocortical volume were maintained at sham levels in rats given fenofibrate. Conclusions The PPARalpha agonist fenofibrate, and to a lesser extent the PPARaplha agonist Wyeth 14643, maintained BMD and bone architecture at sham levels, while the PPARgamma agonist pioglitazone exaggerated bone loss and negatively affected bone architecture, in ovariectomized rats.nb_NO
dc.language.isoengnb_NO
dc.publisherBMC (part of Springer Nature)nb_NO
dc.relation.urihttp://www.biomedcentral.com/1472-6823/11/11
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleThe peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized ratsnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber13nb_NO
dc.source.volume11nb_NO
dc.source.journalBMC Endocrine Disordersnb_NO
dc.source.issue11nb_NO
dc.identifier.doi10.1186/1472-6823-11-11
dc.identifier.cristin836967
dc.description.localcode© 2011 Stunes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.nb_NO
cristin.unitcode194,65,15,0
cristin.unitcode1920,15,0,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.unitnameMedisinsk klinikk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal